All news

AbbVie up 23% year-to-date on immunology growth

Alpha Vantage · Yahoo Finance · · AI-summarised by FinFlash

AbbVie shares have climbed over 23% year-to-date, outpacing the broader market, as Skyrizi and Rinvoq drive immunology revenue growth and the company reduces its reliance on Humira. The stock trades at a forward P/E of 16.39x, with analysts split at 24 buy, 5 hold and 1 sell ratings and an average target of $282.61, marginally below the current price.

Read original source

ABBV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.